The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 11 of 13 of this archive, newest first.
The commonest real-world strategy in this drug class is the least studied one.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
The document is four pages. Three of them are about dates.
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The document is four pages. Three of them are about dates.
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.
The document is four pages. Three of them are about dates.